Business Context and Reporting Period
Company: Alpha Tau Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2025 (Specifically January 27, 2025)
Context: The filing serves to distribute a press release announcing the sharing of "Cornerstone Interim Data" across multiple clinical trials during an upcoming R&D Update Day.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a disclosure of a corporate event (press release) rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary update is the announcement of interim clinical trial data to be presented at a future event.
Guidance, Outlook, and Risks
- Outlook: The Company plans to share interim data from multiple clinical trials at an R&D Update Day.
- Legal Disclaimer: The information furnished in this report and the attached press release is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that Section.
- Risks/Contingencies: No specific risks or contingencies are detailed in the text of this filing.
Investor Verification Checklist
- Verify the date and content of the attached press release (Exhibit 99.1) regarding the R&D Update Day.
- Confirm the specific clinical trials and the nature of the "Cornerstone Interim Data" to be presented.
- Review subsequent filings for the actual presentation of clinical data and any resulting impact on the Company's pipeline valuation.